📊 Midday Market Take

Hey there, hope your Tuesday is going better than the major indices, because the S&P 500 is down 1.54%, the Nasdaq is sliding 2.58%, and even the steadier Dow is off 0.74%. Tech is taking the biggest hit today, dragging everything else along for the ride.

Semiconductor and mega-cap growth names are the clear laggards this session, getting hit hardest as rate-sensitive tech simply has nowhere to hide right now. Keep an eye on whether buyers step in around the Nasdaq's current levels before the close, because a failure to hold here could set a rough tone for Wednesday.

Nuvalent, Inc.

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc.

3 Reasons to Watch NUVL

• GSK Is Buying Nuvalent for $10.6 Billion. Reuters confirmed Tuesday that UK pharma giant GSK has agreed to acquire Nuvalent in a deal valued at $10.6 billion, marking one of GSK's biggest acquisitions in over a decade. That news sent shares up nearly 40% in a single session, which tells you everything you need to know about how the market is pricing this in.
• The Stock Has Been on a Tear All Year. Even before today's acquisition bombshell, Nuvalent was already up more than 61% over the past year, with solid gains of roughly 20% over both the last 30 and 90 days. This wasn't a sleepy stock waiting for a catalyst, it was already building serious momentum heading into the deal announcement.
• Law Firms Are Sniffing Around the Deal Price. Multiple shareholder law firms launched investigations Tuesday into whether Nuvalent's board is getting a fair price for investors in the GSK transaction. That kind of scrutiny sometimes pressures acquirers to bump their offer, so the final price tag may not be the last word on what this company is worth.

Top Market Headlines

These 3 Stocks Lowered Their Share Counts Drastically in Q1

While markets often view large-scale buyback authorizations as positives in and of themselves, authorizations are just one part of the buyback equa...

Elon Musk Warns We May Have Just Six Months Left (Ad)

"Frontier AI" is a point of no return when AI surpasses human intelligence and gains free will. Elon Musk warns this moment could hit by the end of 2026. According to 60-year Wall Street legend, Marc Chaikin, Frontier AI could soon become the only thing that determines which companies make money and which grind to a halt, That's why he's giving away a list of stocks to buy and sell absolutely FREE to help you position your money for a world driven by Frontier AI technology.

3 Dirt-Cheap Stocks to Buy With $1,000 Right Now

Sirius XM, Royal Caribbean, and Upbound are cheap stocks in an elevated market.

Cybersecurity Earnings: 1 AI Standout and 2 Stocks Under Pressure

Cybersecurity earnings delivered a sharp split this week, even as three major names all topped expectations and raised their outlooks.

Hidden AI Crisis Could Bring Crash '62 Times Worse Than the Great Depression' (Ad)

A critical flaw in the AI industry could soon wipe out $33 trillion from the U.S. stock market and cause a potential crash 62 times worse than the Great Depression – if it isn't fixed fast. One small group of companies holds the answer... a breakthrough technology backed by Sam Altman, Elon Musk, Jensen Huang, the White House, and more.

Best Growth Stocks to Buy for June 9th

DVA, XPO, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 9, 2026.

I was right about SpaceX (Ad)

Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.